What can human iPSC-derived disease models add to your drug discovery project?
Date: 18 June, 2020
Time: 10:00 AM, New York / 3:00 PM, London
Presenters: Stefan Braam, CEO Ncardia and Elena Matsa, Director Discovery Technology
Description: Despite many technological developments in the past decade, the output of commercial drugs has been relatively ineffective.
The lack of physiologically-relevant and predictive cell-based assays has been identified as one of the major obstacles.
During this webinar we discuss the advantages, challenges and solutions of implementing human induced pluripotent stem cell (iPSC) technology into drug discovery and development - addressing disease modelling, assay development and phenotypic screening.
Key Learning Objectives
- Understand the benefits and challenges of hiPSC technology
- Learn what needs to be considered when selecting a disease model
- Present best practices in phenotypic assay development
- Demonstrate a high-throughput screen in a model of hypertrophic cardiomyopathy, utilizing hiPSC-derived cardiomyocyte